AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20421832 — intervention group
Group type: COMPARATOR
Intervention: Successful aging health education intervention
Number of subjects: 424
Study 18034919 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA)
Number of subjects: 0
Study 18034919 — intervention group
Group type: COMPARATOR
Intervention: Epoetin
Number of subjects: 0
Study 18034919 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alpha
Number of subjects: 0
Study 15878183 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 0
Study 15878183 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 14516212 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended source (A or B)
Number of subjects: 0
Study 14516212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonattended source
Number of subjects: 0
Study 14516212 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal detection theory application
Number of subjects: 0
Study 10974616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide (CCK‐4) injection, high doses, specific dosage not mentioned, duration not mentioned.
Number of subjects: 0
Study 8868035 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectrophotometric examination of tape strips
Number of subjects: 0
Study 8868035 — intervention group
Group type: COMPARATOR
Intervention: Weighing method
Number of subjects: 0
Study 1611113 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)‐alpha 2b (50 MU dose), intravesical therapy for 10 months, starting 21 days after TUR, once a week for 8 weeks, then once every 15 days for 4 months, and finally once a month for 4 months.
Number of subjects: 85
Study 1611113 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (80 mg) intravesically 0, 24 and 48 h after TUR, followed by IFN‐alpha 2b as in Group 1.
Number of subjects: 85
Study 31959339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1-4 (CF)
Number of subjects: 142
Study 31959339 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1-4 plus panitumumab (P) 9 mg/kg, i.v., day 1 (CFP)
Number of subjects: 142
Study 30967434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 1591
Study 30967434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 1591
Study 30967434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1591
Study 30967434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 mg and 10 mg combined)
Number of subjects: 1591
Study 28079812 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastomeric patient-control module (PCM) connected to balloon pump
Number of subjects: 86
Study 28079812 — intervention group
Group type: COMPARATOR
Intervention: Conventional patient-control module (PCM) connected to balloon pump
Number of subjects: 86
Study 28079812 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastomeric patient-control module (PCM)
Number of subjects: 86
Study 28079812 — intervention group
Group type: COMPARATOR
Intervention: Conventional patient-control module (PCM)
Number of subjects: 86
Study 28079812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both elastomeric and conventional PCM
Number of subjects: 86
Study 25666934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 90
Study 25666934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 23452148 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 82
Study 23452148 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 21352528 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Support Package (DSP)
Number of subjects: 0
Study 21352528 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19884426 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injections with corticosteroid (methylprednisolone acetate)
Number of subjects: 76
Study 19884426 — intervention group
Group type: COMPARATOR
Intervention: Periarticular injections without corticosteroid (no-steroid group)
Number of subjects: 76
Study 17537264 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/day for 3 consecutive days)
Number of subjects: 443
Study 17537264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 17537264 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 443
Study 15581128 — intervention group
Group type: EXPERIMENTAL
Intervention: Boundary constraints applied to event dating
Number of subjects: 200
Study 15581128 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of guesses from the data set
Number of subjects: 200
Study 11329985 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly group visits with a primary care physician, nurse, and pharmacist
Number of subjects: 295
Study 11329985 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 295
Study 9741191 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermovision testing during rehabilitation
Number of subjects: 71
Study 9741191 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 71
Study 7988347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic elastase (10,800 U)
Number of subjects: 28
Study 7988347 — intervention group
Group type: COMPARATOR
Intervention: Dilazep dihydrochloride (300 mg)
Number of subjects: 28
Study 3052894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (CTT) 2g single preoperative dose
Number of subjects: 102
Study 3052894 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (CFX) 2g three perioperative doses plus 0.5g metronidazole
Number of subjects: 102
Study 30870012 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative care intervention delivered by naturopathic doctors (NDs) in conjunction with usual care.
Number of subjects: 0
Study 30870012 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 28566227 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted protease inhibitor plus lamivudine (once-daily lamivudine 300 mg)
Number of subjects: 265
Study 28566227 — intervention group
Group type: COMPARATOR
Intervention: Boosted protease inhibitor monotherapy (once-daily darunavir 800 mg or coformulation of lopinavir/ritonavir)
Number of subjects: 265
Study 26359220 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management group (SG)
Number of subjects: 0
Study 26359220 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 0
Study 24364193 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex oral splint procedure assisted by transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 20
Study 24364193 — intervention group
Group type: COMPARATOR
Intervention: Standard oral splint
Number of subjects: 20
Study 24364193 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (baseline values)
Number of subjects: 20
Study 20890666 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy for 12 months
Number of subjects: 18
Study 20890666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PAP therapy)
Number of subjects: 18
Study 20890666 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy
Number of subjects: 18
Study 19682889 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT (70Gy, 74Gy, 78Gy)
Number of subjects: 791
Study 19682889 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT (74Gy, 78Gy)
Number of subjects: 791
Study 19682889 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT
Number of subjects: 791
Study 19682889 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 791
Study 19682889 — intervention group
Group type: EXPERIMENTAL
Intervention: RT up to 78Gy
Number of subjects: 791
Study 19682889 — intervention group
Group type: COMPARATOR
Intervention: Hormonal treatment
Number of subjects: 791
Study 17090955 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine replacement
Number of subjects: 90
Study 17090955 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 90
Study 15314303 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange of saline during gastrectomy
Number of subjects: 34
Study 15314303 — intervention group
Group type: COMPARATOR
Intervention: No exchange of saline during gastrectomy (Control)
Number of subjects: 34
Study 11349245 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly sessions plus routine inpatient treatment
Number of subjects: 50
Study 11349245 — intervention group
Group type: COMPARATOR
Intervention: Routine inpatient treatment only
Number of subjects: 50
Study 9152658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous procainamide (10 mg.kg‐1)
Number of subjects: 50
Study 9152658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7700072 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril, 2.5 mg/day (n = 12)
Number of subjects: 23
Study 7700072 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 11)
Number of subjects: 23
Study 3295741 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 30
Study 3295741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31621062 — intervention group
Group type: EXPERIMENTAL
Intervention: UHR+ BS criteria (n = 74)
Number of subjects: 133
Study 30608395 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional musculoskeletal therapy pathway
Number of subjects: 249
Study 27698176 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated care (deflation after 1 hour, 2 ml/10‐minute interval)
Number of subjects: 173
Study 27698176 — intervention group
Group type: COMPARATOR
Intervention: Standard care (deflation after 2 hours, additional steps at 3 and 4 hours)
Number of subjects: 173
Study 27698176 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated care
Number of subjects: 173
Study 25627150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle destabilization boot
Number of subjects: 15
Study 25627150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle destabilization sandal
Number of subjects: 15
Study 25627150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle destabilization boot and sandal
Number of subjects: 15
Study 25627150 — intervention group
Group type: COMPARATOR
Intervention: Shod condition
Number of subjects: 15
Study 23782489 — intervention group
Group type: EXPERIMENTAL
Intervention: V7 (10 μg of heat-killed Mycobacterium vaccae)
Number of subjects: 43
Study 23782489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 23782489 — intervention group
Group type: EXPERIMENTAL
Intervention: V7
Number of subjects: 43
Study 23782489 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 43
Study 22379791 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Back-shu points (Xinshu (BL 15), Pishu (BL 20), Gaohuang (BL 43)), once daily for 4 weeks
Number of subjects: 120
Study 22379791 — intervention group
Group type: COMPARATOR
Intervention: Control group (shallow layer of non-acupoints)
Number of subjects: 120
Study 20183647 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD on stimulant medication
Number of subjects: 71
Study 20183647 — intervention group
Group type: COMPARATOR
Intervention: ADHD on placebo
Number of subjects: 71
Study 20183647 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 71
Study 17363335 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 13961
Study 17363335 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening (screen-negative individuals)
Number of subjects: 13961
Study 15865523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar TURP (group 1)
Number of subjects: 60
Study 15865523 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURP (group 2)
Number of subjects: 60
Study 11956266 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic melanoma vaccine for 2 years
Number of subjects: 300
Study 11956266 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 300
Study 9706157 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 544
Study 9706157 — intervention group
Group type: COMPARATOR
Intervention: Operation
Number of subjects: 544
Study 9706157 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis or Operation
Number of subjects: 544
Study 7884105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise program
Number of subjects: 0
Study 7884105 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive exercise training
Number of subjects: 0
Study 7884105 — intervention group
Group type: COMPARATOR
Intervention: Exercise detraining for 10 weeks
Number of subjects: 0
Study 7884105 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise retraining after detraining
Number of subjects: 0
Study 2194126 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1214
Study 2194126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1214
Study 495630 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin plus cefamandole by continuous infusion (C+CC)
Number of subjects: 490
Study 495630 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin plus cefamandole by intermittent infusion (C+IC)
Number of subjects: 490
Study 495630 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin plus tobramycin by continuous infusion (C+T)
Number of subjects: 490
Study 495630 — intervention group
Group type: COMPARATOR
Intervention: Cure rates regardless of antibiotic regimen
Number of subjects: 490
Study 495630 — intervention group
Group type: COMPARATOR
Intervention: Cure rates during documented infections
Number of subjects: 490
Study 31188801 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap surgery with autologous CGF (Group 2)
Number of subjects: 54
Study 31188801 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap surgery with Bio-Oss (Group 3)
Number of subjects: 54
Study 31188801 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap surgery with CGF+Bio-Oss (Group 4)
Number of subjects: 54
Study 31188801 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery alone (Group 1)
Number of subjects: 54
Study 28574453 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation at 800 mg/day
Number of subjects: 0
Study 28574453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn/soy oil)
Number of subjects: 0
Study 28574453 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 0
Study 25369449 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk coronary plaque in patients with NAFLD
Number of subjects: 445
Study 25369449 — intervention group
Group type: COMPARATOR
Intervention: High-risk coronary plaque in patients without NAFLD
Number of subjects: 445
Study 25369449 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of NAFLD with high-risk plaque
Number of subjects: 445
Study 23548942 — intervention group
Group type: EXPERIMENTAL
Intervention: Single euploid blastocyst transfer
Number of subjects: 205
Study 23548942 — intervention group
Group type: COMPARATOR
Intervention: Two untested blastocysts transfer
Number of subjects: 205
Study 21565740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 20
Study 21565740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19164186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (10 mg once a day for children 10 to 24 months of age and 20 mg once a day for older children)
Number of subjects: 700
Study 19164186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 19164186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 700
Study 16490909 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid, 4 mg (n = 32)
Number of subjects: 62
Study 16490909 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, n = 30)
Number of subjects: 62
Study 15124834 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental 028 Extra (E028E)
Number of subjects: 33
Study 15124834 — intervention group
Group type: COMPARATOR
Intervention: Nutrison Standard (NuS)
Number of subjects: 33
Study 11176476 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck preservation
Number of subjects: 70
Study 11176476 — intervention group
Group type: COMPARATOR
Intervention: Resection
Number of subjects: 70
Study 9255195 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of gentamicin (5.0 mg/kg)
Number of subjects: 26
Study 9255195 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily dosing of gentamicin (2.5 mg/kg)
Number of subjects: 26
Study 8370880 — intervention group
Group type: EXPERIMENTAL
Intervention: Iconic cues identical to the signal to be detected
Number of subjects: 0
Study 8370880 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative cues set to 2/3 of the signal frequency
Number of subjects: 0
Study 8370880 — intervention group
Group type: COMPARATOR
Intervention: No cues (maximum uncertainty)
Number of subjects: 0
Study 2950659 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy as a component of combined and complex therapy
Number of subjects: 0
Study 2950659 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy for stage I tumor
Number of subjects: 0
Study 2950659 — intervention group
Group type: COMPARATOR
Intervention: Modified mastectomy after Patey for stage II tumor
Number of subjects: 0
Study 31343550 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure (HP) cuffing (3 × 5-minute unilateral leg occlusion at 50 mm Hg above systolic blood pressure)
Number of subjects: 20
Study 31343550 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure (LP) cuffing (3 × 5-minute unilateral leg occlusion at 20 mm Hg)
Number of subjects: 20
Study 31343550 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) (30‐minute resting)
Number of subjects: 20
Study 31343550 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure (HP) cuffing
Number of subjects: 20
Study 31343550 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure (LP) cuffing
Number of subjects: 20
Study 31343550 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study 28734844 — intervention group
Group type: COMPARATOR
Intervention: CNTO3157 (n = 30)
Number of subjects: 75
Study 28734844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 75
Study 28734844 — intervention group
Group type: COMPARATOR
Intervention: CNTO3157 (n = 8)
Number of subjects: 75
Study 28734844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 75
Study 26545442 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 20
Study 26545442 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 26545442 — intervention group
Group type: COMPARATOR
Intervention: Active rTMS and Sham stimulation
Number of subjects: 20
Study 24716680 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (15 to 45 mg daily)
Number of subjects: 3445
Study 24716680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3445
Study 24716680 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3445
Study 23963688 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/d of ASA (aspirin)
Number of subjects: 125
Study 23963688 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/d of ASA (aspirin)
Number of subjects: 125
Study 21564429 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 300
Study 21564429 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 300
Study 21564429 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus Sulphadoxine-Pyrimethamine (CQ + SP)
Number of subjects: 300
Study 21564429 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study 18503621 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-morphine combination (fentanyl 13.33 mug/mL and morphine 1 mg/mL)
Number of subjects: 54
Study 18503621 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone (2 mg/mL)
Number of subjects: 54
Study 17070173 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cell dose (10^8 cells)
Number of subjects: 66
Study 17070173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cell dose (10^7 cells)
Number of subjects: 66
Study 17070173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cell transplantation)
Number of subjects: 66
Study 12930249 — intervention group
Group type: EXPERIMENTAL
Intervention: T wave alternans (TWA) measured using modified moving average (MMA) analysis from 24-hour ambulatory electrocardiograms (AECGs) during maximum heart rate.
Number of subjects: 1284
Study 12930249 — intervention group
Group type: EXPERIMENTAL
Intervention: TWA in lead V5 during peak heart rate.
Number of subjects: 1284
Study 12930249 — intervention group
Group type: EXPERIMENTAL
Intervention: TWA at 8:00 A.M. in lead V5.
Number of subjects: 1284
Study 12930249 — intervention group
Group type: EXPERIMENTAL
Intervention: TWA level above the 75th percentile during maximum heart rate in lead V1.
Number of subjects: 1284
Study 12930249 — intervention group
Group type: EXPERIMENTAL
Intervention: TWA level above the 75th percentile during maximum heart rate in lead V5.
Number of subjects: 1284
Study 12930249 — intervention group
Group type: EXPERIMENTAL
Intervention: TWA at 8:00 A.M. in lead V1.
Number of subjects: 1284
Study 11193721 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with glucose/amino acids/fat
Number of subjects: 18
Study 11193721 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition with glucose/amino acids
Number of subjects: 18